New Data Position Lazertinib As Strong Contender In 1L NSCLC

Potential Tagrisso Challenger?

 
• By Jung Won Shin
  
lung cancer
New Indication Filing for Lazertinib Expected In Korea in Q1 '23 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D